Summary: Acetylcholinesterase levels were determined in cerebrospinal fluid and serum of 272 patients with various neurological disorders. The patients were ordered in 13 diagnostic groups. The assay employed was an antigen capture assay based on an immobilized monoclonal antibody selective for neuronal acetylcholinesterase (Rasmussen et al., Clin. Chim. Acta 166 (1987) 17-25 (1)).
In 100% of the cases the acetylcholinesterase levels in cerebrospinal fluid were 500-10000 fold higher than expected for a regulär serum-derived protein (0.1 -0.5%) at the intact blood-brain barrier. In both compartments the test vahies showed w'ide variations, which were much greater in serum than in cerebrospinal fluid. No specific relationship was discernible between the values obtained and any of the diagnostic groups, although decreased levels of acetylcholinesterase were found in bacterial and viral meningitis, and elevated levels were found in groups with more chronic diseases.
A possible transfer of acetylcholinesterase from cerebrospinal fluid to blood is discussed.
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Materials and Methods

Samples
Cerebrospinal fluid and blood samples were taken by lumbarand venipuncture respectively, from 272 patients with various neurological disorders (151 males, 121 females; age r nge 17 to 78 years). For reference purposes, blood samples were drawn from 9 healthy persons (students) aged about 25. The blood samples were centrifuged after clotting for one hour. Blood and cerebrospinal fluid samples were then frozen in aliquots at -70°C.
Determination of acetylcholinesterase
The immunoassay for determination of acetylcholinesterase was exactly s described by Rasmussen et al. (1), who also reported the accuracy, specificity and sensitivity of the assay. The monoclonal antibody 4F19 was employed in this study. Values presented are the average of three repeats.
Assay of blood-brain barrier function
Blood-brain barrier function was assayed according to 1. c. (8) and (2) of healthy persons which were all of similar age. With the exception of groups 5 and 8 (p lyneuropathy and · transitoric ischaemic attack, respectively), the various groups show serum values below the detection limit,. although this is less pronounced in groups 4 and 11 (inflammatory disease and miscellaneous diseases respectively); compare or even higher in serum than in cerebrospinal fluid of the same person (20%). Most of these latter values are in the high r nge in both compartments (> 10 U, fig. 1 ). In table l, the percentage of blood-brain barrier impairments per group is compared with the percentage of values below the detection limit and with the percentage of the values which are higher or s high in serum s in cerebrospinal fluid. The data from figure 3 is supplemented in various ways. Thus, groups 12 and 13 (bacterial and viral meningitis respectively, which are undoubtedly serious diseases with decreased acetylcholinesterase levels in cerebrospinal fluid and serum) ( fig. 3) show increased numbers of blood-brain barrier impairments and an increased number of values below the detection limit in the sera (tab. 1). Since, in addition to groups 12 and 13, high percentages of blood-brain barrier impairments are also found in groups 6, 8, and 9 (disk protrusion, transitoric ischaemic attack, and brain infarction), there is no correlation between blood-brain barrier impairment and the values below the detection limit. Serum values, which are äs high or higher than the corresponding values of cerebrospinal fluid, are more or less equally distributed throughout the diagnostic groups, with the exception of group 2 (brain haemorrhage). Group 2, however, is one of the two groups (2 and 8) with the smallest number of cases.
Finally, groups 4 and 11 (inflammatory and miscellaneous diseases), which are the largest groups (52 and 57 cases, respectively), both show a very low percentage of values below the detection limit (tab. 1). They show, however, widely varying elevated values of acetylcholinesterase in their cerebrospinal fluid, and they include the highest values of all measured in this study ( fig. 3 ). These groups are the most heterogeneous and they represent the more chronic diseases. These two groups show average values of all the other parameters studied (tab. 1).
Discussion
It has not been possible in the past to determine reliably the amount of acetylcholinesterase present in biological fluids, since there is neither a Substrate nor an inhibitor absolutely specific for acetylcholinesterase or butyrylcholinesterase 3 ) (9). Erroneous acetylcholinesterase levels have been determined mainly in the serum, which contains an overwhelming preponderance of butyrylcholinesterase. In the present study, an immunoassay was employed based on a monoclonal antibody selective for neuronal acetylcholinesterase (1). There was a slight cross-reactivity (= 10%) with erythrocyte acetylcholinesterase (1). Blood-contaminated cerebrospinal fluid samples, however, did not show elevated acetylcholinesterase levels, thus proving the reliability of the assay.
Eighty percent of the acetylcholinesterase levels determined in the cerebrospinal fluid of 272 patients with various neuropsychiatric disorders were higher (1.5 -10 fold) than the corresponding levels in the sera. In addition to these results, the finding that increasing serum values correspond to increasing cerebrospinal fluid values ( fig. 2 ) Supports the idea of a brain to blood transfer of acetylcholinesterase. Further evidence lends support to the above idea; thus there were many values below the detection limit (17%) in the patients' sera, while the corresponding cerebrospinal fluid values were well above the detection limit and lay over a wide ränge. Finally, it is well established that about 90% of the regulär cerebrospinal fluid protein originates from the serum (10) . It is therefore relevant to ask whether at least some part of acetylcholinesterase in the cerebrospinal fluid may originate from the serum. Neuronal acetylcholinesterase has a relative molecular mass of 290 000, corresponding to a hydrodynamic radius of 5.8 nm (58 Ä) (10) . At the intact blood-cerebrospinal fluid barrier the cerebrospinal fluid level would thus reach not more than 0.1% of the serum level (100%). The average cerebrospinal fluid level determined in this study is, however, 4 fold (400%) that of the corresponding serum level. Even in those cases (10%) where the serum levels are above the cerebrospinal fluid levels the latter are at least 50% of the serum concenträtion. This by far exceeds the 0.1% cerebrospinal fluid concenträtion expected for a regulär serum protein of the size of acetylcholinesterase. Therefore it is justified to assume that the total amount of acetylcholinesterase in the cerebrospinal fluid originates from the nervous parenchyma of the brain. Compared with the central nervous System, the mass of cholinergic neurons in the periphefy is very small indeed. Acetylcholinesterase is the second neuronal enzyme to be described exhibiting cerebrospinal fluid/serum rations > l (the first was neuron-specific enolase (11)), suggesting that it originates in the brain. Detection of brain-derived proteins in cerebrospinal fluid and serum became possible only recently, with the use of sensitive and selective immunoassays (9, 11, 12) .
Due to the large Variation, a specific relatipnship of acetylcholinesterase levels to any of the diagnostic groups is not observed. Some trends are, however, apparent. For example, the values measured in bacterial and viral meningitis (groups 12 and 13) compared with the average of all values, indicate decreased levels of acetylcholinesterase in cerebrospinal fluid and serum and an increased percentage of values below the detection limit, both possibly due to enhanced degradation of proteiiis in both compartments. In cöntrast to these patients with the severe diseases, the chronic inflammatory diseases (group 4) display elevated levels of acetylcholinesterase in cerebrospinal fluid and serum and only a very few values below the detection limit. Most pf the diagnostic. parameters (data not shown) determined in the cerebrospinal fluid and serum of this latter group were normal. Thus groups 4 and 11 (miscellaneous) might both reflect a Situation close to normal with regard to acetylcholinesterase levels, since they comprise large numbers of patients and they do not represent dramatic diseases.
The hope of finding diagnostically significänt altera^· tions has, however, not yet been fulfilled and further evaluation is necessary. The pr^sence of a possibly brain-derived protein in the circulating blood, however, should encourage the search for markers of brain destruction and disease which do not rely on lumbar puncture alone.
